Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML18: Intensive Chemotherapy and Targeted Agents for Older AML/MDS Patients
NCT02272478Phase 3Unknown
- Sponsor
- Cardiff University
- Start
- Oct 2014
- Primary completion
- Feb 2021
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of daunorubicin + cytarabine liposome and quizartinib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Cardiff University. Status: unknown.
02
Drugs
daunorubicin + cytarabine liposomequizartinib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02272478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02272478.